

## Special Issue

# Treatment of Postpartum Depression: Current Status and Future Prospects

### Message from the Guest Editor

Postpartum depression (PPD) is a common complication of childbearing that affects 10–15 % of women in the first few weeks after delivery. Postpartum depression can occur as part of major depressive disorder or bipolar disorder. Left untreated, the illness is associated with significant morbidity, impaired maternal functioning, and disruptions in early mother–infant interaction.

Antidepressants are the mainstay of drug treatment of moderately severe PPD, however, there is limited evidence of their efficacy in the acute or preventative treatment of PPD. Thus, the treatment of PPD remains challenging, leading to sub-optimal maternal, infant, and family outcomes. Focusing on agents that target the neurobiology of PPD may increase the likelihood of developing efficacious drugs. This Special Issue aims to provide a critical appraisal of the extant literature on the pharmacologic and psychotherapeutic management of PPD, and highlight potentially new targets that may allow the development of effective treatments.

---

### Guest Editor

Prof. Dr. Verinder Sharma

Perinatal Clinic St. Joseph's Health Care, Parkwood Institute, Mental Health Care, Western University, Western University, London, ON N6A 3K7, Canada

---

### Deadline for manuscript submissions

closed (30 June 2021)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/71740](https://mdpi.com/si/71740)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).